ABBV presents a situation that can confuse investors: on October 5, 2026, the stock rose to $265.76, only 1.35% below its reported 52-week high, while a new company filing lowered its 2026 adjusted earnings outlook. Those facts can coexist. The filing cited an acquired research-and-development charge, and AbbVie said its third-quarter results were not final. A high share price does not confirm that near-term earnings expectations are unchanged.

Use this October 2026 review as a sequence: confirm the quote and date, separate the price trend from business results, identify what changed in the outlook, then check whether later evidence supports the interpretation. This is a practical guide to reading AbbVie Inc. (NYSE: ABBV), not a prediction or a recommendation to buy or sell.

1. Confirm the date and price before describing the trend

Start with the last completed trading session, not a delayed quote or an intraday price. On Monday, October 5, AbbVie shares closed at $265.76, up 1.12% for the day. The shares had gained for a second consecutive session and were reported 1.35% below their 52-week high of $269.39, reached on September 23. The broader market also rose that day, so the single-session gain was not necessarily a company-specific reaction. These figures are from MarketWatch’s October 5 close report, which identifies Dow Jones and FactSet as its market-data partners.

Write down the time period you are analyzing. “ABBV is near a 52-week high” describes a position within a range; it does not tell you whether the stock is trending up, how quickly it moved there, or whether it has outperformed the market. To judge direction, compare a series of daily or weekly closes and note whether recent swing highs and lows are rising, falling, or mixed.

For a first-pass chart check, Maya, a fictional investor used here only as an example, records the October 5 close, the September 23 high, and the dates of any meaningful pullbacks. She avoids comparing an intraday high with a closing price. Keeping price type and dates consistent prevents a small but common analytical error.

2. Separate the share-price move from the earnings update

The important new company information arrived on October 5. In a Form 8-K, AbbVie said acquired in-process research and development (IPR&D) and milestone expense for the third quarter was estimated at $216 million before tax. The company estimated an unfavorable impact of $0.11 on both GAAP and adjusted diluted earnings per share. Its updated 2026 adjusted diluted EPS range became $13.76 to $13.96, down from the previously announced $13.87 to $14.07. The third-quarter adjusted EPS range was updated to $3.73 to $3.77 from $3.84 to $3.88.

Crucially, AbbVie said September-quarter results had not been finalized and were still subject to closing procedures; the final results could differ from the preliminary estimates. The company also explained that it does not forecast acquired IPR&D and milestone expenses because the timing and occurrence of such transactions are uncertain. Read the original October 5 Form 8-K and preliminary guidance before treating the adjustment as a confirmed final result.

For Maya, the next step is to classify the update correctly. The disclosed adjustment relates to acquired research and milestone costs; by itself, it does not establish that demand for AbbVie medicines weakened. At the same time, an “adjusted” measure is not the same as GAAP earnings. Investors should read the company’s definition and reconciliation rather than assuming that an excluded cost is economically irrelevant. The share price near its high does not resolve this accounting distinction.

3. Check whether the underlying business is growing

The latest completed earnings release available as of October 6 was for the second quarter, published July 31. AbbVie reported $16.990 billion in worldwide net revenue, up 10.2% as reported and 9.5% on an operational basis. “Operational” growth adjusts for currency effects, helping readers compare sales without exchange-rate changes. Adjusted diluted EPS was $3.65, up 22.9%, while GAAP diluted EPS was $2.03. The figures and definitions are in AbbVie’s Q2 2026 financial results.

The product mix is important. Skyrizi revenue rose 24.4% to $5.505 billion, and Rinvoq revenue rose 24.5% to $2.525 billion. Humira revenue fell 35.9% to $756 million. In other words, fast growth in newer immunology medicines was offsetting a steep decline in the older Humira franchise. A useful trend check therefore looks beyond total sales: is growth broad enough to replace products losing exclusivity, and do costs or price competition change the quality of that growth?

The other businesses matter too. AbbVie reported second-quarter neuroscience revenue growth of 20.3%, while oncology revenue declined 1.5% and aesthetics revenue was nearly flat, up 0.3%. This uneven picture makes it risky to extrapolate one successful medicine or division to the company as a whole. Maya compares the portfolio lines over several quarters and checks the company’s June 30, 2026 Form 10-Q for the fuller financial statements, risks, and management discussion.

4. Consider pipeline news without treating it as booked revenue

Drugmakers’ stock trends can respond to trial data, regulatory decisions, and patent competition well before those events appear in sales. On October 5, AbbVie and Genmab announced positive top-line results from a Phase 3 study of epcoritamab with R-CHOP in newly diagnosed diffuse large B-cell lymphoma. The company described an improvement in progression-free survival versus R-CHOP alone. Readers can review the company’s October 5 announcement for the trial context.

A positive topline result is not the same as regulatory approval, a final peer-reviewed publication, or a commercial sales forecast. A sensible analysis tracks the next evidence point—full study data, regulatory filing or review, and eventual uptake—without adding speculative revenue to current results. Pipeline potential can influence investor expectations, but clinical and commercial outcomes remain uncertain.

5. Add the completed acquisition and next reporting date

AbbVie completed its approximately $10.9 billion acquisition of Apogee Therapeutics on September 3. The company said the deal adds clinical-stage candidates in immunology, including programs for atopic dermatitis and asthma, and reaffirmed its earlier full-year adjusted EPS guidance at that time. The September 3 acquisition announcement filed with the SEC also describes expected dilution and integration risks. The October 5 filing then incorporated the later estimated IPR&D expense into the updated outlook.

AbbVie scheduled its third-quarter 2026 results for October 30 before the market opens, according to its October 1 earnings announcement. That release will help investors compare finalized results with the October 5 estimate, revisit revenue by product and portfolio, and assess management’s updated outlook. Until then, the updated EPS figures should be labeled preliminary guidance, not final earnings.

6. Finish with a repeatable self-check

Before concluding that ABBV’s October trend is strong or weak, Maya uses the same short review each time:

• Quote: Is the price current, and is it a closing value or an intraday quote?
• Chart: Are recent weekly highs and lows forming a consistent direction, or is the stock moving sideways near its high?
• Business: Are total and operational revenues growing, and are newer products offsetting declines such as Humira’s?
• Guidance: Is a forecast change tied to operating demand, acquisition costs, or both? Is it preliminary or finalized?
• Next checkpoint: What will the next earnings report or regulatory update clarify, and what evidence would change the current view?

On the information available October 6, 2026, ABBV was close to its reported 52-week high, while the company had just lowered its 2026 adjusted EPS range by $0.11 at both ends because of estimated third-quarter acquired IPR&D and milestone expense. Q2 revenue growth and expanding Skyrizi and Rinvoq sales were constructive business signals; Humira’s decline, pipeline uncertainty, acquisition integration, and the still-preliminary Q3 update remain material considerations. The October 30 report is the next key verification point. This method can organize the evidence, but it cannot forecast the share price or replace an investor’s own risk assessment.

Information cutoff: October 6, 2026. Share prices and company guidance can change. This article is educational and is not individualized investment advice.